Comparison of anesthetic effects of different sedative drugs combined with remifentanil for general anesthesia in bronchoscopy: a randomized controlled trial.
Etomidate caused less intraoperative hypotension than ciprofol or remimazolam during bronchoscopy
Comparison of anesthetic effects of different sedative drugs combined with remifentanil for general anesthesia in bronchoscopy: a randomized controlled trial.
Electronic bronchoscopy, as an important means of invasive diagnosis, exerts strong stimulation on anatomical structures such as the pharynx, glottis, carina.
This study aimed to compare the clinical anesthetic effects of different sedative drugs combined with remifentanil-based general anesthesia in patients undergoing bronchoscopy.
A total of 120 patients scheduled for elective painless electronic bronchoscopy were randomly assigned to the ciprofol group (Group C), etomidate group (Group E), and remimazolam group (Group R).
Only 17.9% on etomidate had low blood pressure vs 45-50% on the other drugs
The incidence of hypotension in Group E was significantly lower than that in Groups C and R (χ² = 9.949, P = 0.007).
There was no statistically significant difference in cough severity among the three groups (χ² = 3.26, P = 0.776).
The incidence of postoperative nausea and vomiting (postoperative nausea and vomiting) was 7.50% in Group C, 7.50% in Group R, and 46.15% in Group E.
The incidence of postoperative nausea and vomiting in Group E was significantly higher than the other two groups (χ² = 24.331, P < 0.001).
Etomidate demonstrates superior hemodynamic stability but carries a higher risk of postoperative nausea and vomiting. In contrast, ciprofol and remimazolam offer better postoperative comfort.
For patients at high risk of hemodynamic instability, etomidate may be preferred with enhanced postoperative nausea and vomiting prophylaxis; for those at high risk of postoperative nausea and vomiting or desiring rapid and comfortable recovery, ciprofol or remimazolam are more suitable options.